EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets
Drug Resistance Updates · 2025-11 · 83 · 101276
DOI: 10.1016/j.drup.2025.101276 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Mingyang Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Neoplastic Stem Cells, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 395 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, The University of Kansas Cancer Center, National University Health System.
Abstract (Originalsprache)
Cancer continues to be a primary cause of death, resulting in substantial mortality and illness globally. It remains a significant global health issue, greatly affecting morbidity and mortality across the world. Therapeutic resistance poses a major challenge to cancer treatments, acting as a significant barrier to the effectiveness of both standard and targeted therapies. This resistance develops through various mechanisms that allow tumor cells to adapt to and escape the damaging effects of chemotherapy, radiation, and targeted therapies. Ultimately, this leads to disease recurrence and progression. This review examines the dual roles of epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) in promoting chemoresistance and metastasis. EMT is a dynamic and reversible biological process in which epithelial cells acquire mesenchymal characteristics, increasing their invasiveness and resistance to programmed cell death. CSCs are a subset of cancer cells with the ability to self-renew and play a crucial role in tumor relapse and resistance to treatment. EMT and CSCs are closely interconnected, collaboratively enhancing cancer cell plasticity, metastatic ability, and treatment resistance. The initiation of EMT in cancer cells can generate a CSC-like population, which promotes tumor recurrence and spread. This interaction highlights the importance of targeting both EMT and CSC pathways to develop more effective treatment strategies that address treatment resistance and prevent metastasis. Promising approaches include using natural substances, small molecules, and nanotechnology to block critical signaling pathways and interfere with resistance mechanisms. A more thorough understanding of the molecular factors underlying EMT and CSC plasticity is crucial for crafting personalized treatments that target tumor heterogeneity and improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Neurosurgery, Binzhou Medical University Affiliated Shengli Oilfield Central Hospital, Dongying, China.
- Department of Clinical Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
- Department of Rehabilitation, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Faculty of Health Sciences, University of Almeria, Carretera Sacramento s/n, La Canada, Almería 04120, Spain.
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Electronic address: weiruqiongxibanya@163.com.
Förderung
- NCI NIH HHS
- The University of Kansas Cancer Center
- National University Health System
- National Cancer Institute
- Government of Singapore Ministry of Education
Zitieren
APA
Jiang, M., Wang, J., Li, Y., Zhang, K., Wang, T., Bo, Z., Lu, S., Rodríguez, R. A., Wei, R., Zhu, M., Nicot, C., & Sethi, G. (2025). EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets. Drug Resistance Updates, 83, 101276. https://doi.org/10.1016/j.drup.2025.101276
Vancouver
Jiang M, Wang J, Li Y, Zhang K, Wang T, Bo Z, et al. EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets. Drug Resistance Updates. 2025;83:101276. doi:10.1016/j.drup.2025.101276
BibTeX
@article{Jiang2025,
author = {Jiang, Mingyang and Wang, Jinlong and Li, Yize and Zhang, Ke and Wang, Tao and Bo, Zhandong and Lu, Shenyi and Rodríguez, Raquel Alarcón and Wei, Ruqiong and Zhu, Mingtao and Nicot, Christophe and Sethi, Gautam},
title = {EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets},
journal = {Drug Resistance Updates},
year = {2025},
volume = {83},
pages = {101276},
doi = {10.1016/j.drup.2025.101276}
}
EUVIMED